Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Outcomes with myeloid malignancies.

Bart L Scott1, Brenda M Sandmaier

  • 1Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA 98109, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radioimmunotherapy as a targeted strategy of reduced-intensity conditioning for allogeneic transplantation in leukemia.

Frontiers in oncology·2026
Same author

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.

Leukemia & lymphoma·2026
Same author

Case Report: donor cell-derived leukemia after allogeneic stem cell transplantation for metastatic renal cell carcinoma.

Frontiers in immunology·2026
Same author

[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.

Blood·2026
Same author

Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma.

Frontiers in oncology·2026
Same author

Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.

Blood·2026

Reduced-intensity conditioning (RIC) expands eligibility for allogeneic stem cell transplantation (HCT) in myeloid malignancies. While RIC reduces non-relapse mortality, it may increase relapse risk, particularly in relapsed patients.

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Allogeneic stem cell transplantation (HCT) offers a potential cure for myeloid malignancies.
  • Conventional myeloablative HCT is limited by age and comorbidities.
  • Reduced-intensity conditioning (RIC) was developed to broaden HCT eligibility.

Purpose of the Study:

  • To evaluate the efficacy and safety of RIC regimens in myeloid malignancies.
  • To compare outcomes of RIC versus conventional myeloablative HCT.
  • To identify patient and disease factors influencing RIC outcomes.

Main Methods:

  • Review of retrospective studies comparing RIC and myeloablative HCT.
  • Analysis of non-relapse mortality (NRM) and relapse-related mortality.

Related Experiment Videos

  • Stratification of outcomes based on patient age, comorbidities, and disease status (remission vs. relapse).

    • Main Results:

    • RIC regimens have successfully reduced NRM, expanding HCT eligibility.
    • Most studies show decreased NRM but increased relapse-related mortality with RIC compared to myeloablative HCT.
    • Patients in remission at HCT with RIC show reduced NRM without increased relapse, while relapsed patients may have increased relapse risk.

    Conclusions:

    • RIC is a valuable strategy for selected myeloid malignancy patients, reducing NRM.
    • The balance between NRM and relapse risk with RIC requires careful consideration, especially in relapsed patients.
    • Prospective studies are needed to optimize RIC regimens based on patient and disease characteristics.